Twelve more patients in a hundred stay recurrence-free at 2 years — on top of pembrolizumab alone. INTerpath-001 (LBA1, #ESMO26): resected stage IIB–IV melanoma; intismeran autogene + pembrolizumab vs pembrolizumab (n=1,137).
Early release after embargo breach — confirm at PS I (Long). @ProfGLongMIA
61 views · 0 likes · 0 reposts · 1 reply
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org- Mustafa Özdoğan, MD@ozdogan_md
Circulating — confirm at PS I (Long). Solid so far: 24-mo RFS 82.2% vs 70.0%, HR 0.58 (0.45–0.75). Absolute +12.2 pp · NNT ≈8 if rates hold. DMFS 88.5% vs 80.2%, HR 0.62. Grade ≥3 AE 23.6% vs 20.3%. Piecewise signal from early release: curves flat ~first 6 months, then HR ~0.42 after immunization. OS immature — that remains the practice-changing ask.
Source: Mustafa Özdoğan, MD · x.com